Yang Y et al. found that ANXA1, as an FPR1 agonist, was more highly expressed in poorly differentiated human primary gliomas compared with lower‐grade tumours, and accounted for stimulating GBM cell growth and invasion.10 The gene discussed is ANXA1; the disease is central nervous system cancer.